 |
08.05.2010
Ironwood Pharmaceuticals Provides Second Quarter 2010 Investor Update
|
22.9 KB |
| |
CAMBRIDGE, Mass., Aug 05, 2010 (BUSINESS WIRE) -- Ironwood
Pharmaceuticals, Inc. (NASDAQ: IRWD) today provided an update on its
business activities for the second quarter of 2010.
Second Quarter 2010 Highlights
Linaclotide
Both confirmatory Phase 3 clinical trials being carried out by
Ironwood and its ...
|
|
08.02.2010
Ironwood Pharmaceuticals Announces Second Quarter 2010 Investor Update Call
|
13.3 KB |
| |
CAMBRIDGE, Mass., Aug 02, 2010 (BUSINESS WIRE) -- Ironwood
Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will issue
its second quarter 2010 investor update after the U.S. financial markets
close on Thursday, August 5, 2010. In connection with this announcement,
Ironwood will host a conference call and webca...
|
|
07.28.2010
Ironwood Pharmaceuticals Announces Upcoming Presentation at Wedbush Life Sciences MAC Best Ideas 2010
|
13.0 KB |
| |
CAMBRIDGE, Mass., Jul 28, 2010 (BUSINESS WIRE) -- Ironwood
Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced that Michael
Higgins, Ironwood's chief financial officer and chief operating officer,
will present at Wedbush Life Sciences MAC Best Ideas 2010 on Tuesday,
August 3, 2010 at 8:35 a.m. Eastern Time at Le Par...
|
|
05.26.2010
Ironwood Pharmaceuticals Announces Participation in J.P. Morgan Biotech CEO/CFO Conference Call
|
12.8 KB |
| |
CAMBRIDGE, Mass., May 26, 2010 (BUSINESS WIRE) -- Ironwood
Pharmaceuticals, Inc. (NASDAQ: IRWD) today announced it will
participate in the J.P. Morgan Biotech: CEO/CFO Conference Call Series
at 10:00 a.m. Eastern Time on Friday, May 28, 2010.
Conference call details are as follows:
Live conference call (U...
|
|
05.11.2010
Ironwood Pharmaceuticals Provides First Quarter 2010 Investor Update
|
23.4 KB |
| |
CAMBRIDGE, Mass., May 11, 2010 (BUSINESS WIRE) -- Ironwood
Pharmaceuticals, Inc. (NASDAQ: IRWD) today provided an update on its
business activities for the first quarter of 2010.
First Quarter 2010 Highlights
Linaclotide
In March, the final patients were enrolled into each of the two
confirmatory Phase...
|
|
|
